¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ceramide lactoside lipidosis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ceramide
    ¼¼¶ó¹Ìµå
  • lipidosis
    ÁöÁúÁõ
  • lactoside
    ¶ôÅä½Ãµå
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ceramide
    ¼¼¶ó¹Ìµå
  • lipidosis
    ÁöÁúÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ceramide
    ¼¼¶ó¹Ìµå
  • lipidosis
    ÁöÁúÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • galactocerebroside lipidosis
    °¶¶ôÅä¼¼·¹ºê·Î»çÀ̵å ÁöÁúÁõ
  • phosphatide lipidosis
    ÀÎÁöÁú¼º À¯ÁöÁõ(ìÝò·òõàõ×¾ò·ñø).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ceramide
    ¼¼¶ó¸¶À̵å.
  • d-Glucose ceramide
    d-Æ÷µµ´ç ¼¼¶ó¹Ìµå
  • galactocerebroside lipidosis
    °¶¶ôÅä¼¼·¹ºê·Î»çÀ̵å ÁöÁúÁõ
  • lipidosis
    Áö¹æÁõ, ÁöÁú(ÃàÀû)Áõ.
  • lipidosis
    ÁöÁúÁõ(¡­ñø)
  • phosphatide lipidosis
    ÀÎÁöÁú¼º À¯ÁöÁõ(ìÝò·òõàõ×¾ò·ñø).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ceramide lactoside
    ¼¼¶ó¸¶ÀÌµå ¶ôÅä»çÀ̵å
  • glucosylceramide lipidosis
    ±Û·çÄڽǼ¼¶ó¸¶À̵å Áö¹æÁõ(ò·Û¸ñø)
  • lipidosis
    ÁöÁúÁõ(ò·òõñø)
  • ceramide
    ¼¼¶ó¸¶À̵å
  • ceramide glycoside
    ¼¼¶ó¸¶ÀÌµå ±Û¶óÀÌÄÚ»çÀ̵å
  • glycosyl ceramide
    ±Û¶óÀÌÄÚ½Ç ¼¼¶ó¸¶À̵å
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
CDH ceramide dihexoside; congenital diaphragmatic hernia; congenital dislocation of hip; congenital dysp...
CER capital expenditure review; ceramide; conditioned emotional response; control electrical rhythm; cor...
CTH ceramide trihexoside; chronic tension headache; cystathionase
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CER Ceramide
CMH Ceramide monohexoside
GalCer Galactosyl ceramide
CGalt UDP-galactose-ceramide galactosyl transferase
CGT UDP-galactose:ceramide galactosyl transferase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lactoside
    ¶ôÅä»çÀ̵å
    Æ÷µµ´ç°ú °¥¶ôÅ佺ÀÇ º¹ÇÕü.
  • lipidosis
    ÁöÁú ÃàÀûÁõ
    ÁöÁúÀÇ ºñÁ¤»óÀû ÃàÀûÀ» ÃÊ·¡ÇÏ´Â ¼¼Æ÷ ÁöÁú ´ë»ç Àå¾ÖÀÇ ÃÑĪ.
  • ceramide
    ¼¼¶ó¸¶À̵å
    õ¿¬¿¡ Á¸ÀçÇÏ´Â ½ºÇÎ°í¸®Çǵå·Î¼­ ½ºÇΰí½ÅÀÇ NH2°¡ Áö¹æ»ê ¾Æ½Ç ÄÚ¿¡ÀÌ À¯µµÃ¼·Î ¾Æ½ÇÈ­µÊÀ¸·Î½á N-acetyls
  • ceramide trihexosidase
    ¼¼¶ó¸¶ÀÌµå Æ®¶óÀÌÇí¼Ò»çÀ̵å, »ï´ç ¼¼¶ó¸¶À̵å
    Fabry º´¿¡¼­ ÃàÀûµÇ´Â ÁÖµÈ s
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
ceramide lactoside lipidosis An inherited disorder associated with an accumulation of ceramide lactoside due to a deficiency of ceramide lactosidase; results in progressive brain damage with liver and spleen enlargement.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
ceramide lactoside A lactosylceramide that accumulates in individuals with ceremide lactoside liposis.
Compare: cytolipin.
(05 Mar 2000)
ganglioside lipidosis Any disease characterised, in part, by the abnormal accumulation within the nervous system of specific gangliosides, e.g., GM2 gangliosidosis, Tay-Sachs disease, caused by hexosaminidase A enzyme deficiency with accumulation of GM2 ganglioside
Synonym: gangliosialidosis, ganglioside lipidosis.
(05 Mar 2000)
glycolipid lipidosis <disease> Lysosomal storage disease caused by a deficiency of alpha-galactosidase a and resulting in an accumulation of globotriaosylceramide in the renal and cardiovascular systems.
The disease is characterised by telangiectatic skin lesions, renal failure, and disturbances of the cardiovascular, gastrointestinal, and central nervous systems.
Inheritance: x-linked.
(08 Mar 2000)
cerebral lipidosis Any one of a group of inherited diseases characterised by failure to thrive, hypertonicity, progressive spastic paralysis, loss of vision and occurrence of blindness, usually with macular degeneration and optic atrophy, convulsions, and mental deterioration; associated with abnormal storage of sphingomyelin and related lipids in the brain. Four types are recognised as clinically and enzymatically distinct: 1) infantile type (Tay-Sachs disease, GM2 gangliosidosis) due to a deficiency of hexosaminidase A; 2) early juvenile type (Jansky-Bielschowsky or Bielschowsky's disease); 3) late juvenile type (Spielmeyer-Vogt disease; Spielmeyer-Sjogren disease; Batten-Mayou disease; ceroid lipofuscinosis); and 4) adult type (Kufs disease).
Synonym: cerebral lipidosis.
(05 Mar 2000)
cerebroside lipidosis <disease> A chronic congenital disease of lipid metabolism caused by a deficiency of the beta-glucocerebrosidase enzyme. The defect is most common in Ashkenazi Jews. Clinical features are hepatosplenomegaly (enlargement of liver and spleen) and in severe early onset forms of the disease, with neurological dysfunction.
Inheritance: autosomal recessive.
(27 Sep 1997)
sphingomyelin lipidosis <disease> A family of severe lysosomal storage diseases resulting in an accumulation of sphingomyelin and other phospholipids in the reticuloendothelial system.
The best studied forms are due to deficiency of sphingomyelinase and it is more common in Ashkenazi Jews than other groups.
Clinical signs include foam cells in the blood and marrow, hepatosplenomegaly and neurologic degeneration. Diagnosis is confirmed by enzyme assay on leukocytes or fibroblasts and specific mutations in the gene are now recognised.
(29 Dec 1997)
sulfatide lipidosis <radiology> Dysmyelinating disease, autosomal recessive, aryl sulfatase A -- absent from urine and serum, most present by 2 yrs, die at 3-4 yrs, may arise at any age, CT: decreased density of white matter, primarily in centrum semiovale, with or without focal gall bladder defects (!)
(12 Dec 1998)
lipidosis Hereditary abnormality of lipid metabolism that results in abnormal amounts of lipid deposition; classification is typically based on the responsible enzymatic deficiency and type of lipid involved. Such enzymatic activity takes place in the lysosomes, and the abnormal products appear as lysosomal storage diseases. Sphingolipidoses make up the largest portion of recognised lipidoses, including abnormal metabolism of gangliosides, ceramides, and cerebrosides.
Origin: Lipid + G. -osis, condition
(05 Mar 2000)
ceramide <chemical> An N acyl sphingosine, the lipid moiety of glycosphingolipids.
(18 Nov 1997)
ceramide 1-phosphorylcholine <biochemistry> A sphingolipid in which the head group is phosphoryl choline. A close analogue of phosphatidylcholine. In many cells the concentration of sphingomyelin and phosphatidylcholine in the plasma membrane seems to bear a reciprocal relationship.
(18 Nov 1997)
ceramide-activated protein kinase <enzyme> Mw 97 kD; stimulation of kinase takes place during sphingomyelin pathway; has membrane-bound activity capable of phosphorylating a peptide derived from the sequence surrounding thr(699) of the epidermal growth factor receptor; has role in signal transduction for tumour necrosis factor
Registry number: EC 2.7.10.-
Synonym: cap kinase
(26 Jun 1999)
ceramide-activated protein phosphatase <enzyme> Belongs to the heterotrimeric subfamily of the pp2a group of serine-threonine protein phosphatases; involved in ceramide-mediated signal transduction; inhibited by okadaic acid
Registry number: EC 3.1.3.-
Synonym: ceramide-stimulated phosphatase, capp (enzyme)
(26 Jun 1999)
ceramide cholinephosphotransferase <enzyme> Do not confuse with phosphatidylcholine-ceramide phosphotransferase which is also called sphingomyelin synthase
Registry number: EC 2.7.8.3
Synonym: sphingomyelin synthetase, phosphorylcholine-ceramide transferase, cdpcholine-n-acylsphingosine cholinephosphotransferase
(26 Jun 1999)
ceramide dihexoside The accumulated glycolipid noted in glycolipid lipidosis.
(05 Mar 2000)
ceramide glycanase <enzyme> Glycosphingolipid splitting enzyme from leech; cleaves linkage between oligosaccharide and ceramide
Registry number: EC 3.2.1.-
Synonym: cer glycanase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á